Kaléo Receives 100th Patent
Wednesday, January 27, 2016
Richmond-based pharmaceutical company kaléo has received a new patent for its medical device designed to quickly treat opioid overdoses, a problem that claims tens of thousands of lives each year.
The patent, issued by the U.S. Patent and Trademark Office on Jan. 19, covers aspects of the electronic voice and visual instruction technology included in the company’s FDA-approved product called Evzio. The latest patent is a significant milestone for kaléo because it is the 100th patent that has been awarded to the company by domestic and international patent authorities.
“This will be the twentieth patent for our naloxone product, EVZIO, listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, also known as the Orange Book,” said Evan Edwards, co-founder and Vice President of Product Development and Industrialization. “Our Human Factors Engineering product development process led to the invention of EVZIO, and other innovative products that are designed with the end user in mind.”
Human Factors Engineering (HFE) is central to kaléo’s collaborative approach to product development. Kaléo utilizes HFE, in which patients and caregivers are directly involved, in the development and design of potentially life-saving medical products intended to be used in emergency situations.
“Administering emergency medicines correctly, especially in stressful and potentially life-threatening situations, is a major concern for physicians, patients and their loved ones,” said Spencer Williamson, President and CEO of kaléo. “Our process of collaborating with patients helps ensure that every aspect of our product design and usability is evaluated through their real world experiences.”
The company has invested more than $100 million in the research, development and commercialization of EVZIO, the first take-home naloxone auto-injection system approved by the FDA for immediate administration in settings where opioids may be present, such as in a home where most opioid overdose emergencies occur.
Ron Gunn, Chief Operating Officer, said, “We are proud to achieve this important milestone and continue to invest in R&D for the next generation of innovative technologies that fulfill unmet medical needs.”